Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion

Bibliography

• Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006;368:733-43
   PubMed Web of Science ®Google Scholar
• Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999;82:233-48
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2) LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 2004;22:345-61
   PubMed Web of Science ®Google Scholar
• Pawankar R, Baena-Cagnani CE, Bousquet J, et al. State of world allergy report 2008: allergy and chronic respiratory diseases. World Allergy Organ J 2008;1(suppl):S4-17
   Google Scholar
• Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(Suppl 85):17-25
   PubMed Web of Science ®Google Scholar
• Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007;28:3-9
   PubMed Web of Science ®Google Scholar
• Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007;120:381-7
   PubMed Web of Science ®Google Scholar
• HealthStar Communications, Inc., in partnership with Schulman, Ronca and Bucuvalas, Inc. Allergies in America: a landmark survey of nasal allergy sufferers. Executive summary. Florham Park, NJ: Altana Pharma US, Inc., 2006
   Google Scholar
• Shedden A, Iezzoni D. Congestion and its impact on sleep in individuals with allergic rhinitis. Presented at: XXV Congress of the European Academy of Allergology and Clinical Immunology; June 10-14, 2006; Vienna, Austria
   Google Scholar
• Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Respir Med 2005;4:439-46
   PubMedGoogle Scholar
• Craig TJ, Ferguson BJ, Krouse JH. Sleep impairment in allergic rhinitis, rhinosinusitis, and nasal polyposis. Am J Otolaryngol 2008;29:209-17
   PubMed Web of Science ®Google Scholar
• Long AA. Findings from a 1000-patient internet-based survey assessing the impact of morning symptoms on individuals with allergic rhinitis. Clin Ther 2007;29:342-51
   PubMed Web of Science ®Google Scholar
• Stull DE, Roberts L, Frank L, Heithoff K. Relationship of nasal congestion with sleep, mood, and productivity. Curr Med Res Opin 2007;23:811-9
   PubMed Web of Science ®Google Scholar
• Flemons WW, Tsai W. Quality of life consequences of sleep-disordered breathing. J Allergy Clin Immunol 1997;99:S750-6
   PubMed Web of Science ®Google Scholar
• Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81(pt 2):478-518
   PubMed Web of Science ®Google Scholar
• Lehman JM, Blaiss MS. Selecting the optimal oral antihistamine for patients with allergic rhinitis. Drugs 2006;66:2309-19
   PubMed Web of Science ®Google Scholar
• Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000;105(pt 2):S622-7
   PubMed Web of Science ®Google Scholar
• Nathan RA, Finn AF Jr, LaForce C, et al. Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study. Ann Allergy Asthma Immunol 2006;97:389-96
   PubMed Web of Science ®Google Scholar
• Sussman GL, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:100-6
   PubMed Web of Science ®Google Scholar
• Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol 1995;96:139-47
   PubMed Web of Science ®Google Scholar
• Bertrand B, Jamart J, Marchal JL, Arendt C. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology 1996;34:91-6
   PubMedGoogle Scholar
• Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002;89:485-91
   PubMed Web of Science ®Google Scholar
• Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001;56(Suppl 65):14-20
   PubMed Web of Science ®Google Scholar
• Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001;56:1077-80
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Cirillo I, Vizzaccaro A, et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005;5:1800-8
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Nayak A, Rooklin A, Danzig M. Efficacy and safety of desloratadine/pseudoephedrine tablet, 2.5/120 mg two times a day, versus individual components in the treatment of patients with seasonal allergic rhinitis. Allergy Asthma Proc 2005;26:391-6
   PubMed Web of Science ®Google Scholar
• Pleskow W, Grubbe R, Weiss S, Lutsky B. Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005;94:348-54
   PubMed Web of Science ®Google Scholar
• Schenkel E, Corren J, Murray JJ. Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc 2002;23:325-30
   PubMed Web of Science ®Google Scholar
• Grubbe RE, Lumry WR, Anolik R. Efficacy and safety of desloratadine/pseudoephedrine combination vs its components in seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2009;19:117-24
   PubMed Web of Science ®Google Scholar
• Horak F, Stubner P, Zieglmeyer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003;58:481-5
   PubMed Web of Science ®Google Scholar
• Clarinex [prescribing information]. Kenilworth, NJ: Schering-Plough Corporation; 2005
   Google Scholar
• Aerius summary of product characteristics. Kenilworth, NJ: Schering-Plough; 2006
   Google Scholar
• Clarinex D [prescribing information]. Kenilworth, NJ: Schering-Plough Corporation; 2006
   Google Scholar
• Zyrtec [prescribing information]. New York, NY: Pfizer Inc; 2006
   Google Scholar
• Allegra [prescribing information]. Bridgewater, NJ: sanofi-aventis; 2007
   Google Scholar
• Xyzal [prescribing information]. Smyrna, GA: UCB, Inc.; 2008
   Google Scholar
• Xyzal® (levocetirizine dihydrochloride) summary of product characteristics. Berkshire, England: UCB Pharma Ltd; 2008
   Google Scholar
• Claritin [package insert]. Kenilworth, NJ: Schering Corp; 2007
   Google Scholar
• Zyrtec D 12-hour [package insert]. New York, NY: Pfizer, Inc.; 2003
   Google Scholar
• Allegra D 24-hour [prescribing information]. Bridgewater, NJ: sanofi-aventis; 2006
   Google Scholar
• Claritin D [package insert]. Kenilworth, NJ: Schering Corp; 2007
   Google Scholar
• Beconase [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2005
   Google Scholar
• Veramyst [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2008
   Google Scholar
• Nasonex [prescribing information]. Kenilworth, NJ: Schering-Plough Corporation; 2005
   Google Scholar
• Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 2000;50:345-52
   PubMed Web of Science ®Google Scholar
• Kreutner W, Hey JA, Chiu P, Barnett A. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 2000;50:441-8
   PubMed Web of Science ®Google Scholar
• Genovese A, Patella V, De Crescenzo G, et al. Loratadine and desethoxylcarbonyl loratadine inhibit the immunological release of mediators from human Fc epsilon RI + cells. Clin Exp Allergy 1997;27:559-67
   PubMed Web of Science ®Google Scholar
• Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001;31:1369-77
   PubMed Web of Science ®Google Scholar
• Affrime M, Gupta S, Banfield C, Cohen A. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet 2002;41(Suppl 1):13-9
   PubMed Web of Science ®Google Scholar
• Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004;18:399-411
   PubMed Web of Science ®Google Scholar
• Vuurman EF, Rikken GH, Muntjewerff ND, et al. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 2004;60:307-13
   PubMed Web of Science ®Google Scholar
• Wilken JA, Kane RL, Ellis AK, et al. A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:375-85
   PubMed Web of Science ®Google Scholar
• Salerno SM, Jackson JL, Berbano EP. Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis. Arch Intern Med 2005;165:1686-94
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Jalowayski AA, Vogt K, et al. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol 2006;96:363-8
   PubMed Web of Science ®Google Scholar
• Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy 2007;62:359-66
   PubMed Web of Science ®Google Scholar
• Rossi GA, Tosca MA, Passalacqua G, et al. Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. Allergy 2005;60:416-7
   PubMed Web of Science ®Google Scholar
• Simons FE, Prenner BM, Finn A Jr. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003;111:617-22
   PubMed Web of Science ®Google Scholar
• Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam Pract 2002;3:14
   PubMedGoogle Scholar
• Haye R, Hoye K, Berg O, et al. Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study [ISRCTN23032971]. Clin Mol Allergy 2005;3:3
   PubMedGoogle Scholar
• Keith PK, Luciuk G. Effectiveness of desloratadine 5 mg once daily in patients with symptoms of seasonal allergic rhinitis: results of a Canadian multicenter, open-label trial. Clin Ther 2007;29:419-26
   PubMed Web of Science ®Google Scholar
• Kim K, Sussman G, Hebert J, et al. Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2006;96:460-5
   PubMed Web of Science ®Google Scholar
• Pradalier A, Neukirch C, Dreyfus I, Devillier P. Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. Allergy 2007;62:1331-4
   PubMed Web of Science ®Google Scholar
• Greiff L, Persson CG, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol 2002;89:413-8
   PubMed Web of Science ®Google Scholar
• Bachert C, Christian JV, Plenker A. Desloratadine in the treatment of seasonal allergic rhinitis. Clin Drug Investig 2002;22(Suppl 2):43-52
   Web of Science ®Google Scholar
• Chiang Y-C, Shyur S-D, Chen T-L, et al. Cetirizine plus pseudoephedrine versus loratadine plus pseudoephedrine for perennial allergic rhinitis. Asian Pac J Allergy Immunol 2006;24:97-103
   PubMed Web of Science ®Google Scholar
• Grosclaude M, Mees K, Pinelli ME, et al. Cetirizine and pseudoephedrine retard, given alone or in combination, in patients with seasonal allergic rhinitis. Rhinology 1997;35:67-73
   PubMedGoogle Scholar
• Berkowitz RB, McCafferty F, Lutz C, et al. Fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhinitis symptoms, as assessed in an allergen exposure unit. Allergy Asthma Proc 2004;25:335-43
   PubMed Web of Science ®Google Scholar
• Legal requirements for the sale and purchase of drug products containing pseudoephedrine, ephedrine, and phenylpropanolamine [press release]. Washington, DC: US Food and Drug Administration; May 8, 2006. Available from: www.fda.gov/CDER/news/methamphetamine.htm. [Last accessed 15 April 2009]
   Google Scholar
• Nasal decongestants get new sales restrictions [press release]. London, England: Medicines and Healthcare products Regulatory Agency; August 29, 2007. Available from: www.mhra.gov.uk/NewsCentre/Pressreleases/CON2032216. [Last accessed 15 April 2009]
   Google Scholar
• Pseudoephedrine rescheduling—information for sponsors. Canberra, Australia: Australian Government Department of Health and Ageing Administration Therapeutic Goods Agency; September 15, 2008. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/annual-report2007.htm. [Last accessed 15 April 2009]
   Google Scholar
• Gawchik S, Goldstein S, Prenner B, John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 2003;90:416-21
   PubMed Web of Science ®Google Scholar
• Scadding GK, Lund VJ, Jacques LA, Richards DH. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy 1995;25:737-43
   PubMed Web of Science ®Google Scholar
• Anolik R. Mometasone Furoate Nasal Spray with Loratadine Study Group. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunology 2008;100:264-71
   PubMed Web of Science ®Google Scholar
• Lumry W, Prenner B, Corren J, Wheeler W. Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily. Ann Allergy Asthma Immunol 2007;99:267-72
   PubMed Web of Science ®Google Scholar
• Bernstein JA. Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin 2007;23:2441-52
   PubMed Web of Science ®Google Scholar
• Rachelefsky GS. National guidelines needed to manage rhinitis and prevent complications. Ann Allergy Asthma Immunol 1999;82:296-305
   PubMed Web of Science ®Google Scholar
• Shturman-Ellstein R, Zeballos RJ, Buckley JM, Souhrada JF. The beneficial effect of nasal breathing on exercise-induced bronchoconstriction. Am Rev Respir Dis 1978;118:65-73
   PubMed Web of Science ®Google Scholar
• Scharf M, Berkowitz D. Effects of desloratadine and alcohol coadministration on psychomotor performance. Curr Med Res Opin 2007;23:313-21
   PubMed Web of Science ®Google Scholar
• LaForce C, Dockhorn RJ, Prenner BM, et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol 1996;76:181-8
   PubMed Web of Science ®Google Scholar
• Berger WE, White MV, and the Rhinitis Study Group. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 2003;91:205-11
   PubMed Web of Science ®Google Scholar
• Verbruggen K, Van Cauwenberge P, Bachert C. Anti-IgE for the treatment of allergic rhinitis - and eventually nasal polyps? Int Arch Allergy Immunol 2008;148:87-98
   PubMed Web of Science ®Google Scholar
• Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;(1):CD001936
   Google Scholar